EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy

Tomoo Sato, Masahiro Nagai, Osamu Watanabe, Tatsuro Misu, Norihiro Takenouchi, Ryuichi Ohkubo, Satoshi Ishihara, Yoshio Tsuboi, Masahisa Katsuno, Masanori Nakagawa, Takuya Matsushita, Yasuhiro Aso und 8 weitere

Journal of Neurology · 2024

DOI: 10.1007/s00415-024-12239-x ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Neurology, 2024. Verfasst von Tomoo Sato und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Paraparesis, Tropical Spastic, Neopterin, Human T-lymphotropic virus 1. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyowa Kirin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic neurodegenerative disease. This multicenter, randomized phase 3 study evaluated the efficacy and safety of 0.3 mg/kg intravenous mogamulizumab, a monoclonal antibody targeting-CC chemokine receptor 4, every 12 weeks in HAM/TSP patients. This study comprised a 24-week double-blind, placebo-controlled period, 24-week open-label period, and extension treatment period. The primary endpoint was the proportion of patients with a ≥ 1-grade improvement in the Osame motor disability score (OMDS). Secondary endpoints were changes in HTLV-1 proviral load, 10-m timed walk, cerebrospinal fluid (CSF) neopterin levels, and safety. The exploratory endpoint was CSF chemokine C-X-C motif ligand 10 (CXCL10) levels. Thirty-four and 33 patients were randomized to mogamulizumab and placebo arms, respectively. At the end of the double-blind period, no significant difference was found in the OMDS improvement rate or other secondary efficacy endpoints assessing motor activities. However, the mogamulizumab arm showed a significant decrease in HTLV-1 proviral load (− 59.39 ± 29.91% vs. placebo 2.32 ± 36.31%) and CSF neopterin ( p < 0.001)/CXCL10 levels ( p = 0.004). The baseline OMDS pattern and the 60–80% HTLV-1 proviral load reduction were sustained through the open-label and extension treatment periods. Although a higher incidence of rash (69.2%) was reported, the safety profile was similar compared with a previous phase 1/2a study. We found no significant difference in clinical benefit; however, mogamulizumab may provide long-term clinical benefit by preventing disease progression, as CSF neopterin/CXCL10 levels are associated with long-term prognosis in HAM/TSP. Clinical Trial Registration Number: NCT03191526 (registered date: 6-June-2017).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedParaparesis, Tropical SpasticNeopterinHuman T-lymphotropic virus 1HumansDouble-Blind MethodMaleMiddle AgedFemaleAdultAgedChemokine CXCL10Viral LoadTreatment Outcome

Stichwörter der Autor:innen

CXCL10Human T-cell leukemia virus type 1-associated myelopathy/tropical spastic parap…KW-0761MogamulizumabNeopterinOsame motor disability score

Substanzen

Antibodies, Monoclonal, HumanizedmogamulizumabNeopterinChemokine CXCL10CXCL10 protein, human

Autor:innen und Institutionen

  • Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Department of Neurology, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Department of Neurology and Clinical Pharmacology, Ehime University Hospital, Toon, Japan.
  • Department of Neurology, Kagoshima City Hospital, Kagoshima, Japan.
  • Department of Neurology, Tohoku University Hospital, Sendai, Japan.
  • Department of Microbiology and Department of Neurology, Kansai Medical University, Hirakata, Japan.

Förderung

  • Kyowa Kirin

Zitieren

APA

Sato, T., Nagai, M., Watanabe, O., Misu, T., Takenouchi, N., Ohkubo, R., Ishihara, S., Tsuboi, Y., Katsuno, M., Nakagawa, M., Matsushita, T., Aso, Y., Matsuura, E., Tokashiki, T., Mukaino, A., Adachi, H., Nakanishi, K., Yamaguchi, Y., Yamaguchi, S., & Yamano, Y. (2024). Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy. Journal of Neurology. https://doi.org/10.1007/s00415-024-12239-x

Vancouver

Sato T, Nagai M, Watanabe O, Misu T, Takenouchi N, Ohkubo R, et al. Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy. Journal of Neurology. 2024. doi:10.1007/s00415-024-12239-x

BibTeX
@article{Sato2024,
  author = {Sato, Tomoo and Nagai, Masahiro and Watanabe, Osamu and Misu, Tatsuro and Takenouchi, Norihiro and Ohkubo, Ryuichi and Ishihara, Satoshi and Tsuboi, Yoshio and Katsuno, Masahisa and Nakagawa, Masanori and Matsushita, Takuya and Aso, Yasuhiro and Matsuura, Eiji and Tokashiki, Takashi and Mukaino, Akihiro and Adachi, Hiroaki and Nakanishi, Kaoru and Yamaguchi, Yusuke and Yamaguchi, Saaya and Yamano, Yoshihisa},
  title = {Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy},
  journal = {Journal of Neurology},
  year = {2024},
  doi = {10.1007/s00415-024-12239-x}
}
Kostenlos starten →